NGNina Lykkegaard Gehr

Nina Lykkegaard Gehr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nina Lykkegaard Gehr has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Lise Ventzel

    University Hospital of Southern Denmark

    4 shared publications
  • Signe Timm

    Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark

    3 shared publications
  • Lars Henrik Jensen

    Department of Oncology, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark

    2 shared publications
  • Nanna Brix Finnerup

    Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    2 shared publications
  • Søren Rafael Rafaelsen

    Department of Regional Health Research, Faculty of Health Serviced, University of Southern Denmark, Odense, Denmark

    2 shared publications
  • Torben Frøstrup Hansen

    Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark

    2 shared publications

Latest Publications

  • Ultrasonographic assessment of chemotherapy-induced peripheral neuropathy after oxaliplatin treatment: an exploratory study

    by Nina Lykkegaard Gehr, Malene Roland Vils Pedersen, Torben Frøstrup Hansen, Lars Henrik Jensen, Signe Timm, Lise Ventzel, Søren Rafael Rafaelsen

    Background: Oxaliplatin is used in colorectal cancer treatment (CRC) but frequently causes chemotherapy-induced peripheral neuropathy (CIPN), a cumulative and potentially chronic adverse event. Reliable non-invasive methods for the early detection and monitoring of CIPN are lacking. Shear wave elastography (SWE) is an ultrasound-based technique that quantifies peripheral nerve stiffness and may enable CIPN assessment. Purpose: To evaluate the feasibility of SWE for detecting CIPN from oxaliplatin treatment in CRC. Material and Methods: In this prospective, single-blinded study, patients with stage III–IV CRC receiving oxaliplatin-based (n = 18) or non-oxaliplatin chemotherapy (n = 12) were assessed at baseline, 3 months, and 6 months. Tibial nerve SWE, cross-sectional area, and diameter were measured using a standardized ultrasound protocol. CIPN symptoms were recorded through structured interviews, yielding composite scores (0–10), with possible CIPN defined as ≥2 points. Healthy controls (n = 9) underwent a single SWE evaluation. Linear mixed-effects models and non-parametric tests were used for longitudinal and group comparisons. Results: Nerve diameter increased over time in both groups (+1.50 mm, 95% confidence interval = 0.78–2.21; P P P = 0.04). Conclusion: SWE is a feasible, non-invasive method, and tibial nerve stiffness was modestly associated with CIPN symptom severity at 6 months. These findings are hypothesis-generating, and larger studies with validated neuropathy instruments are warranted to confirm clinical utility.

  • Open Access

    Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy

    by Nina Lykkegaard Gehr, Christina Mortensen, Tore B. Stage, Malene Roland Vils Pedersen, Søren Rafael Rafaelsen, Jonna Skov Madsen, Dorte Aalund Olsen, Signe Timm, Lars Henrik Jensen, Torben Frøstrup Hansen, et al.

    Purpose: Oxaliplatin-induced peripheral neuropathy (OIPN) is a chronic, debilitating late effect following oxaliplatin treatment. Neurofilament light chain (NfL) is a structural protein found in nerve axons that was investigated upon oxaliplatin exposure in vitro and in vivo correlated to symptoms of OIPN in colorectal cancer patients receiving oxaliplatin. Methods: Human sensory neurons, derived from induced pluripotent stem cells, were exposed to clinically relevant concentrations of oxaliplatin in vitro, with NfL concentrations measured in the cell medium. The prospective clinical study included patients with colorectal cancer undergoing chemotherapy therapy with or without oxaliplatin. Possible OIPN was defined as bilateral presence of numbness and/or presence of pricking sensations in the feet documented in an interview at the time of blood sampling prior to, 3, and 6 months after initiating treatment. Results: Oxaliplatin exposure led to a dose-dependent NfL increase in vitro. In the clinical cohort of 30 patients (18 in the oxaliplatin group), NfL levels rose at 3 and 6 months compared to controls. NfL level changes correlated to OIPN symptoms at the 6-month timepoint (rho 0.81, p < 0.001). However, the interindividual variation was substantial, and most patients showed only a minor increase in NfL. Conclusion: Both in vitro and clinical data indicate that oxaliplatin exposure results in elevated NfL levels. Further prospective studies are needed to evaluate NfL as an early biomarker for OIPN, specifically focusing on the timing of blood sampling during chemotherapy treatment to enable the timely reduction of oxaliplatin.


  • Open Access

    Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors: A cross-sectional study

    by Nina Lykkegaard Gehr, Signe Timm, Kristine Bennedsgaard, Kasper Grosen, Erik Jakobsen, Anders Bonde Jensen, Jeanette Dupont Rønlev, Ann Søegaard Knoop, Nanna B. Finnerup, Lise Ventzel


  • Open Access

    A systematic review and meta-analysis of randomized controlled head-to-head trials of recommended drugs for neuropathic pain

    by Ayda Asadizadeh Sadegh, Nina Lykkegaard Gehr, Nanna Brix Finnerup

    Neuropathic pain is a challenging chronic pain condition. Limited knowledge exists regarding the relative effectiveness of pharmacological treatments, and differences in trial design and impact of the placebo response preclude indirect comparisons of efficacy between drug classes. The purpose of this systematic review and meta-analysis of head-to-head trials was to compare the efficacy and tolerability of drugs recommended for neuropathic pain. We conducted a systematic review and meta-analysis of direct-comparison double-blind randomized trials. Primary outcomes were mean change in pain intensity and number of responders with a 50% reduction in pain intensity. Secondary outcomes encompassed quality of life, sleep, emotional functioning, and number of dropouts because of adverse events. We included 30 trials (4087 patients), comprising 16 crossover and 14 parallel-group design studies. All studies were conducted in adults, and the majority were investigator-initiated trials. We found moderate-quality evidence for equivalence (no clinically relevant difference) between tricyclic antidepressants (TCA) and gabapentin/pregabalin with a combined mean difference in pain score of 0.10 (95% CI −0.13 to 0.32). We could not document differences between TCA and serotonin–noradrenaline reuptake inhibitors (SNRI), between SNRI and gabapentin/pregabalin, or between opioids and TCA (low quality of evidence). We found more dropouts because of adverse events with SNRI and opioids compared with TCA (low quality of evidence). We did not identify any studies that included topical treatments. This systematic review of direct-comparison studies found evidence for equivalence between TCA and gabapentin/pregabalin and fewer dropouts with TCA than SNRI and opioids.


  • Open Access

    Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients – a randomized controlled trial. (OxaNeuro)

    by Nina Lykkegaard Gehr, Páll Karlsson, Signe Timm, Signe Christensen, Christian Andreas Hvid, Jana Peric, Torben Frøstrup Hansen, Lotte Lauritzen, Nanna Brix Finnerup, Lise Ventzel

    Background: Oxaliplatin-induced peripheral neuropathy (OIPN) in general and painful OIPN in particular is a debilitating late effect that severely affects cancer survivors’ quality of life and causes premature cessation of potentially lifesaving treatment. No preventive treatments and no effective treatment for chronic OIPN exist despite many attempts. One of several suggested mechanisms includes neuroinflammation as a contributing factor to OIPN. Fish oil containing long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFAs) are precursors to specialized proresolving mediators that mediate the resolution of inflammation. Our primary hypothesis is that a high supplementation of n-3 LCPUFAs will lower the prevalence and severity of OIPN. Methods: The OxaNeuro project is an investigator-initiated, multicenter, double-blinded, randomized, placebo-controlled clinical study. We will include 120 patients eligible to receive adjuvant oxaliplatin after colorectal cancer surgery. Patients will receive fish oil capsules containing n-3 LCPUFAs or corn oil daily for 8 months. The primary endpoint is the prevalence of OIPN at 8 months defined as relevant symptoms, including one of the following: abnormal nerve conduction screening, abnormal vibration threshold test, abnormal skin biopsy, or abnormal pinprick test. Additional endpoints include the intensity and severity of OIPN-related neuropathic pain, patient-reported OIPN symptoms, quality of life, mental health symptoms, body composition, and cognitive evaluation. Furthermore, we will evaluate inflammatory biomarkers in blood samples and skin biopsies, including the potential OIPN biomarker neurofilament light protein (NfL) which will be measured before each cycle of chemotherapy. Discussion: If readily available fish oil supplementation alleviates OIPN prevalence and severity, it will significantly improve the lives of both cancer survivors and palliative cancer patients receiving oxaliplatin; it will improve their quality of life, optimize chemotherapeutic treatment plans by lowering the need for dose reduction or premature cessation, and potentially increase survival. Trial registration: ClinicalTrial.gov identifier: NCT05404230 Protocol version: 1.2, April 25th. 2023


  • Virtual Double Staining: A Digital Approach to Immunohistochemical Quantification of Estrogen Receptor Protein in Breast Carcinoma Specimens

    by Nina Lykkegaard Andersen, Anja Brügmann, Giedrius Lelkaitis, Søren Nielsen, Michael Friis Lippert, Mogens Vyberg

    Visual assessment of immunohistochemically detected estrogen receptor protein is prone to interobserver and intraobserver variation due to its subjective evaluation. The aim of this study was to validate a new image analysis system based on virtual double staining (VDS) by comparing visual and automated scorings of ER in tissue microarrays of breast carcinomas. Tissue microarrays were constructed of 112 consecutive resection specimens of breast carcinomas. Immunohistochemistry assays for ER and pancytokeratin was applied on separate serial sections. ER scoring was visually performed by 5 observers using the histoscore (H-score) method. The Visiopharm ER image analysis protocol (APP) software application using VDS technique was applied separating stromal cells from carcinoma and other epithelial cells based on the pancytokeratin reaction. Using color deconvolution, polynomial filters, and nuclear segmentation the APP determined the percentage of positive cells and their intensity, and calculated the resulting H-score. On the basis of 1% cutoff VDS was perfectly correlated with visual assessment (κ=1). Using H-score, a very high agreement between VDS and visual ER assessment was seen (R 2=0.950). Image analysis has the attributes to eliminate the shortcomings of visual ER evaluation by generating automated, reproducible, and objective results of ER assessment.